Pfizer has announced that the FDA has given a nod t0 a Prior
Approval Supplement for Embeda (morphine sulfate and naltrexone hydrochloride)
Extended Release Capsules CII.
The Supplement included an update to the Embeda
manufacturing process, addressing the pre-specified stability requirement that
caused the voluntary recall of Embeda from the market in March 2011. Pfizer
expects product availability in the second quarter of next year. Read more.
No comments:
Post a Comment